Hwang Shin, Song Gi-Won, Jung Dong-Hwan, Park Gil-Chun, Ahn Chul-Soo, Moon Deok-Bog, Ha Tae-Yong, Kim Ki-Hun, Lee Sung-Gyu
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ann Hepatobiliary Pancreat Surg. 2017 Feb;21(1):11-16. doi: 10.14701/ahbps.2017.21.1.11. Epub 2017 Feb 28.
BACKGROUNDS/AIMS: Mycophenolate mofetil (MMF) has wide inter- and intra-individual variability of mycophenolic acid (MPA) after liver transplantation (LT). On this study, we aimed to analyse the intra-individual variability of MPA concentration in stable adult LT recipients receiving MMF monotherapy and develop a method to determine the target level in the situation of wide intra-individual variability.
This retrospective cross-sectional study included 30 LT recipients. All patients received MMF monotherapy at a dose of 500 mg twice daily for ≥2 years and were divided into two groups based on renal function. MPA concentration-associated values were presented as mean with standard deviation and coefficient of variation (CV).
The normal renal function group (n=15) showed a mean 12-hour MPA concentration of 2.5±0.5 µg/ml (range, 1.8±0.5 to 3.6±0.7 µg/ml) and a mean CV of 20.4±7.7% (range, 8.7% to 39.4%). In the renal dysfunction group (n=15), the 12-hour MPA concentration fluctuated more widely with a mean value of 3.7±0.9 µg/ml (range, 2.8±0.8 to 5.1±1.2 µg/ml) and a mean CV of 24.5±4.9% (range, 17.1% to 37.5%). The 12-hour MPA concentration was significantly higher in the renal dysfunction group, as compared to the normal renal function group (=0.001); whereas, the CV was not significantly different between the two groups (=0.093).
We determined the inter- and intra-individual variability of 12-hour MPA concentration after LT. The results suggested that therapeutic drug monitoring of MPA is necessary due to the inter-individual and intra-individual variability of MMF pharmacokinetics, especially in LT recipients with renal dysfunction.
背景/目的:肝移植(LT)后,霉酚酸酯(MMF)的霉酚酸(MPA)在个体间和个体内存在广泛的变异性。在本研究中,我们旨在分析接受MMF单药治疗的稳定成年LT受者中MPA浓度的个体内变异性,并开发一种在个体内变异性较大的情况下确定目标水平的方法。
这项回顾性横断面研究纳入了30名LT受者。所有患者均接受剂量为500mg,每日两次的MMF单药治疗≥2年,并根据肾功能分为两组。MPA浓度相关值以平均值、标准差和变异系数(CV)表示。
正常肾功能组(n = 15)的12小时MPA平均浓度为2.5±0.5μg/ml(范围为1.8±0.5至3.6±0.7μg/ml),平均CV为20.4±7.7%(范围为8.7%至39.4%)。在肾功能不全组(n = 15)中,12小时MPA浓度波动更大,平均值为3.7±0.9μg/ml(范围为2.8±0.8至5.1±1.2μg/ml),平均CV为24.5±4.9%(范围为17.1%至37.5%)。与正常肾功能组相比,肾功能不全组的12小时MPA浓度显著更高(P = 0.001);然而,两组之间的CV没有显著差异(P = 0.093)。
我们确定了LT后12小时MPA浓度的个体间和个体内变异性。结果表明,由于MMF药代动力学的个体间和个体内变异性,尤其是在肾功能不全的LT受者中,对MPA进行治疗药物监测是必要的。